Browsing by Author "Shiraishi, Kenjirou"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    The utility of intraventricular pressure gradient for early detection of chemotherapy-induced subclinical cardiac dysfunction in dogs
    (Mdpi, 2021-04-08) Matsuura, Katsuhiro; Shiraishi, Kenjirou; Mandour, Ahmed S.; Sato, Kotomi; Shimada, Kazumi; Goya, Seijirow; Yoshida, Tomohiko; Kitpipatkun, Pitipat; Hamabe, Lina; Uemura, Akiko; Yılmaz, Zeki; Ifuku, Mayumi; Iso, Takeshi; Takahashi, Ken; Tanaka, Ryou; YILMAZ, ZEKİ; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0001-9836-0749; A-9637-2008
    Simple SummaryCardiotoxicity is a serious side effect of doxorubicin in cancer patients due to the risk of development of heart failure. Early detection of doxorubicin-induced cardiomyopa-thy (DXR-ICM) has become a major objective to reduce heart failure in cancer patients. Echocar-diography is the gold standard method to diagnose cardiac diseases when cardiac dysfunction is prominent; however, it still cannot predict or early diagnose heart failure before functional de-cline. The intraventricular blood flow is characterized by intraventricular pressure gradients (IVPG) that created due to the suction of blood by the ventricles. Currently, advanced imaging techniques allow non-invasive assessment of IVPG from color M-mode echocardiography (CMME) after image processing for the clinical setting. Studies revealed that IVPG indices are promising for the early diagnosis of cardiac dysfunction. In this study, we aimed to investigate the usefulness of IVPG to detect cardiac function changes after DXR administration in dogs.Early detection of doxorubicin (DXR)-induced cardiomyopathy (DXR-ICM) is crucial to improve cancer patient outcomes and survival. In recent years, the intraventricular pressure gradient (IVPG) has been a breakthrough as a sensitive index to assess cardiac function. This study aimed to evaluate the usefulness of IVPG for the early detection of chemotherapy-related cardiac dysfunction. For this purpose, six dogs underwent conventional, speckle tracking, and color M-mode echocardiography concomitantly with pressure-and-volume analysis by conductance catheter. The cardiac function measurements were assessed before DXR administration (baseline, Pre), at the end of treatment protocol (Post), and at 1.5 years follow-up (Post2). The result showed a significant reduction in the left ventricular end-systolic pressure-volume (Emax: 4.4 +/- 0.7, 6.1 +/- 1.6 vs. 8.4 +/- 0.8 mmHg/mL), total-IVPG (0.59 +/- 0.12, 0.62 +/- 0.15 vs. 0.86 +/- 0.12 mmHg), and mid-IVPG (0.28 +/- 0.12, 0.31 +/- 0.11 vs. 0.48 +/- 0.08 mmHg), respectively in Post2 and Post compared with the baseline (p < 0.05). Mid-to-apical IVPG was also reduced in Post2 compared with the baseline (0.29 +/- 0.13 vs. 0.51 +/- 0.11). Meanwhile, the fraction shortening, ejection fraction, and longitudinal strain revealed no change between groups. Total and mid-IVPG were significantly correlated with Emax (R = 0.49; p < 0.05, both) but only mid-IVPG was a predictor for Emax (R-2 = 0.238, p = 0.040). In conclusion, this study revealed that impairment of contractility was the initial changes observed with DXR-ICM in dogs and only IVPG could noninvasively detect subclinical alterations in cardiac function. Color M-mode echocardiography-derived IVPG could be a potential marker for the early detection of doxorubicin cardiomyopathy.